CMS Open Payments · Tool
Swedish Orphan Biovitrum Ab vs Otsuka Pharmaceutical Development & Commercialization, Inc.
Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.
A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.
Compare Different Companies
Relationship comparison
Which recorded payment profile is more concentrated?
Swedish Orphan Biovitrum Ab has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 679, versus 421 for the other company. Its single largest recorded recipient represents 0.1% of that company's General Payments recipient total.
HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.
- Swedish Orphan Biovitrum Ab
- HHI 679 · top recipient 0.1%
- Ranked #1,181 of 1,838 companies by HHI
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- HHI 421 · top recipient 0.1%
- Ranked #1,359 of 1,838 companies by HHI
Payment Overview
Swedish Orphan Biovitrum Ab
- Total Payments
- $14.7M
- % of Industry
- 0.1%
- Transactions
- 299
- Avg per Transaction
- $49.2K
- Recipients
- 55
- Avg per Recipient
- $267.3K
- Payment Types
- 3
- Top Payment Type
- Travel and Lodging
- Total Payments
- $14.8M
- % of Industry
- 0.1%
- Transactions
- 5,037
- Avg per Transaction
- $2.9K
- Recipients
- 4,515
- Avg per Recipient
- $3.3K
- Payment Types
- 7
- Top Payment Type
- Consulting Fee
Highlighted values indicate the higher figure for each metric.
Total payments compared
Swedish Orphan Biovitrum Ab vs Otsuka Pharmaceutical Development & Commercialization, Inc. - total reported payments in CMS Open Payments PY2024
Payment Types Breakdown
Swedish Orphan Biovitrum Ab
0.9%
0.8%
0.2%
Otsuka Pharmaceutical Development & Commercialization, Inc.
19.9%
1.1%
1.0%
1.0%
0.8%
0.1%
Top 5 General-Payment Recipients
This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.
Swedish Orphan Biovitrum Ab
- 1
MICHAEL TARANTINO
$29,820.09 · 2 txns
- 2
PUJA KHANNA
$24,516.52 · 6 txns
- 3
EDWARD BEHRENS
$24,215.38 · 3 txns
- 4
HERBERT BARAF
$24,111.16 · 5 txns
- 5
RACHAEL GRACE
$22,555.33 · 3 txns
Otsuka Pharmaceutical Development & Commercialization, Inc.
- 1
BRUCE BERGER
$458,120.30 · 28 txns
- 2
LINDA CAPPIELLO-LINDSLEY
$349,301.30 · 8 txns
- 3
HASSAN MALIK
$253,953.54 · 14 txns
- 4
MARYAM SABA
$166,680.00 · 9 txns
- 5
HAOLING WENG
$155,309.11 · 6 txns
Summary Comparison
| Metric | Swedish Orphan Biovitrum Ab | Otsuka Pharmaceutical Development & Commercialization, Inc. |
|---|---|---|
| Total Payments | $14.7M | $14.8M |
| % of Industry Total | 0.1% | 0.1% |
| Transaction Count | 299 | 5,037 |
| Avg per Transaction | $49.2K | $2.9K |
| Recipient Count | 55 | 4,515 |
| Avg per Recipient | $267.3K | $3.3K |
| Payment Type Count | 3 | 7 |
| Top Payment Type | Travel and Lodging | Consulting Fee |
Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.